Iridex Corporation announced that it will relocate its headquarters from Mountain View to San Jose, California. The company signed a non‑binding letter of intent on January 26, 2026 for a 31,000‑sq‑ft lease and plans to complete the move in fiscal 2026, which runs from January 1 to December 31, 2026.
The relocation is projected to generate approximately $0.4 million in savings in fiscal 2026 and $0.6 million in annualized savings thereafter. The savings stem from lower rent, reduced overhead, and a streamlined office footprint that still preserves access to Bay Area talent.
CEO Patrick Mercer said the move will lower operating expenses while maintaining access to Bay Area talent and supporting reduced manufacturing operations. The relocation is part of Iridex’s broader cost‑reduction program under new leadership, which has already cut operating expenses by 12 % in Q3 2025 and improved the company’s net loss from $1.9 million to $1.6 million.
Iridex’s Q3 2025 results showed revenue of $12.5 million, an 8 % year‑over‑year increase, and operating expenses that fell 12 % from the prior year. The company’s focus on cost discipline and strategic consolidation is expected to strengthen its financial position and support continued innovation in its MicroPulse® technology for treating glaucoma and retinal diseases.
The non‑binding nature of the lease means Iridex has not yet committed to the terms, but the company expects the move to provide a material incremental savings stream while keeping its manufacturing footprint lean and its talent pool intact.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.